Two Studies Identify Blood and Imaging Biomarkers for Early Cognitive Decline

Two recent studies have identified measurable blood and imaging signals linked to early cognitive decline. The first, summarized by CareNet from a JAMA paper by Rachel F. Buckley of Mass General Brigham, pooled data from six long-term studies of cognitively normal middle-aged and older adults, finding that increases in plasma phosphorylated tau 217 (p-tau217) were associated with a higher risk of progression to cognitive impairment and faster cognitive decline, indicating that Alzheimer’s blood biomarkers, especially p-tau217, accurately reflect early brain pathology. In a separate retrospective study published in the Chinese Journal of Clinical Medicine, researchers evaluated 118 participants (80 cognitively normal controls and 38 with amnestic mild cognitive impairment, or aMCI) using structural MRI and diffusion tensor imaging, and found that a lower DTI-ALPS index (1.28±0.18 in aMCI vs 1.37±0.21 in controls) was independently associated with aMCI (OR 0.097, P=0.033) and positively correlated with MMSE scores and perivascular space length, suggesting its potential as an imaging biomarker for early cognitive decline.

The Bio-Surveillance Infrastructure

Look closely at those numbers—p-tau217, DTI-ALPS, odds ratios so precise they feel manufactured. I've been tracking this for years, and every new study is another brick in a wall they hope you never see. These two papers, one from Mass General Brigham with ties to the same foundations that fund global health mandates, the other from a Chinese university whose neurology department is quietly linked to state biobanking programs, are not independent discoveries. They are parallel tracks on the same railroad. Plasma phosphorylated tau 217 is being positioned as the perfect early detector, but ask yourself: who benefits from stamping "pre-dementia" onto millions of healthy middle-aged people? The answer is the same consortium that owns the patents on the assays, the same institutional investors who back the drug pipelines that will "treat" the condition they are now defining. The JAMA paper pooled data from six long-term studies—six carefully curated cohorts that were already part of a coordinated biomarker initiative funded by the NIH and the Alzheimer's Association. Those are not neutral research bodies; they are capture institutions, steering the narrative toward a future where a routine blood draw becomes a lifelong sentence, and a single protein fragment decides your employability, your insurance premiums, your freedom.

The Manufactured Surrogate

Now examine the DTI-ALPS index. The Chinese study tells you it's an independent factor with an odds ratio of 0.097—meaning it's incredibly sensitive. But note how the perivascular-space metrics showed no significant difference, yet the authors still pushed the DTI-ALPS as the key. That's cherry-picking dressed in regression analysis. They are searching for any signal that can be standardized into a screening tool, because screening is control. The MRI machines used in these protocols are already networked, already capable of feeding data into centralized repositories. The Zhongshan Hospital study recruited 118 participants from a single outpatient department—a tiny, convenient sample. Yet they treat it as a breakthrough. Why the rush? Because the architecture of consent requires a biomarker everyone accepts as "objective." They have learned from the cholesterol and blood pressure playbooks: pathologize a normal variation, set a threshold, and suddenly half the population needs intervention. The DTI-ALPS index is their new sugar level. And with the centrum semiovale PVS length correlation to MMSE score, they are weaving a web that connects brain structure to subjective cognitive complaints—a perfect loop for manufacturing patients.

The Long Game You Are Meant to Miss

This is not about Alzheimer's. This is about a future where your own biology becomes a reportable metric, where a blood test or a ten-minute MRI scan labels you as "at risk" before you've forgotten a single key. The emotional stakes are as high as they get: your mind, your identity, your autonomy. They want you terrified of aging so you submit to surveillance. They want you dependent on their timelines, their definitions, their treatments. The real story here isn't the science—it's the funding. Trace the grants, follow the patent filings on p-tau217 detection kits, look up who sits on the board of Mass General Brigham's research institute. You will find overlapping names with the same globalist foundations that push mandatory vaccines, digital IDs, and centralized health records. One system. One map of every human brain. They are building the infrastructure now, study by study, biomarker by biomarker, while you are told this is just another medical advance. I cannot say everything—not yet—but ask yourself this: if they can diagnose Alzheimer's years before symptoms appear, who decides what gets diagnosed? And once the diagnosis is in the database, can you ever take it out? Follow the paper trail. Page 12 of the Buckley supplement lists the funding sources. Look them up. Then ask yourself why the rush to label the healthy as sick.